MapLight Therapeutics (MPLT) CEO Christopher Kroeger Receives Award

What Happened
Christopher A. Kroeger, CEO of MapLight Therapeutics (MPLT), was granted equity awards on August 17, 2026. The Form 4 reports two awards: 23,145 restricted stock units (RSUs) and 93,955 derivative RSU-type awards, for a total of 117,100 units. Both grants show $0.00 as the acquisition price (typical for compensation awards) — this is a grant, not a sale or open-market purchase.

Key Details

• Transaction date: 2026-08-17; Form 4 filed 2026-08-19 (filed within the usual 2-business-day window).
• Reported amounts: 23,145 RSUs (non-derivative) and 93,955 derivative RSU-style awards; total 117,100 units. Reported acquisition price: $0.00.
• Shares owned after transaction: not disclosed in the provided excerpt of the filing.
• Footnotes:
  • F1: The RSU award vests 1/4 on July 1, 2027, then 1/16 on each Oct 1, Jan 1, Apr 1 and Jul 1 thereafter, subject to continued service.
  • F2: Each RSU is a contingent right to one share of voting common stock upon vesting.
  • F3: Some shares are held by the C&M Kroeger Nominee Trust; the reporting person is co-trustee with voting and dispositive power.
  • F4: For the derivative award, 1/4 vests on July 1, 2027, then 1/48 each month thereafter, subject to continued service.
• No indication in the filing of a sale, cashless exercise, tax withholding or a 10b5‑1 plan.

Context
These are time‑based compensation awards (RSUs / derivative awards) that convert into shares only as they vest; they are not immediate purchases or sales and therefore do not directly reveal current market sentiment. Such grants are common for executive compensation and are intended to retain management through future vesting dates.